Literature DB >> 24372680

Antifungal drug resistance mechanisms in pathogenic fungi: from bench to bedside.

M Cuenca-Estrella1.   

Abstract

The phenotypic methods for identification of antifungal resistance are reliable procedures, and MIC determination by reference techniques is the gold standard to detect resistant clinical isolates. In recent years, progress has been made towards the description of resistance mechanisms at molecular level. There are methods of detection that can be useful for clinical laboratories, but lack of standardization precludes their full and effective integration in the routine daily practice. The molecular detection of Candida resistance to azoles and to echinocandins and of Aspergillus resistance to triazoles can be clinically relevant and could help to design more efficient prevention and control strategies. This text reviews the present state of the detection of mechanisms of resistance at the molecular level in Candida spp. and Aspergillus spp. and its relevance to clinical practice.
© 2013 The Authors Clinical Microbiology and Infection © 2013 European Society of Clinical Microbiology and Infectious Diseases.

Entities:  

Keywords:  Aspergillus; Candida; mutations; mycosis; tandem repeat

Mesh:

Substances:

Year:  2014        PMID: 24372680     DOI: 10.1111/1469-0691.12495

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  28 in total

1.  Echinocandin failure case due to a previously unreported FKS1 mutation in Candida krusei.

Authors:  Rasmus Hare Jensen; Ulrik Stenz Justesen; Annika Rewes; David S Perlin; Maiken Cavling Arendrup
Journal:  Antimicrob Agents Chemother       Date:  2014-03-31       Impact factor: 5.191

Review 2.  The Emerging Threat of Antifungal Resistance in Transplant Infectious Diseases.

Authors:  Ilan S Schwartz; Thomas F Patterson
Journal:  Curr Infect Dis Rep       Date:  2018-02-05       Impact factor: 3.725

3.  Changing Azole Resistance: A Secondary Analysis of the MUTT I Randomized Clinical Trial.

Authors:  N Venkatesh Prajna; Prajna Lalitha; Revathi Rajaraman; Tiruvengada Krishnan; Anita Raghavan; Muthiah Srinivasan; Kieran S O'Brien; Michael Zegans; Stephen D McLeod; Nisha R Acharya; Jeremy D Keenan; Thomas M Lietman; Jennifer Rose-Nussbaumer
Journal:  JAMA Ophthalmol       Date:  2016-06-01       Impact factor: 7.389

Review 4.  The antifungal pipeline: a reality check.

Authors:  John R Perfect
Journal:  Nat Rev Drug Discov       Date:  2017-05-12       Impact factor: 84.694

Review 5.  The molecular mechanism of azole resistance in Aspergillus fumigatus: from bedside to bench and back.

Authors:  Xiaolei Wei; Yuanwei Zhang; Ling Lu
Journal:  J Microbiol       Date:  2015-01-28       Impact factor: 3.422

6.  Genomewide Elucidation of Drug Resistance Mechanisms for Systemically Used Antifungal Drugs Amphotericin B, Caspofungin, and Voriconazole in the Budding Yeast.

Authors:  Cigdem Balkan; Ilkcan Ercan; Esin Isik; Esra Sahin Akdeniz; Orhan Balcioglu; Marie Kodedová; Olga Zimmermannová; Muhammed Dundar; Hana Sychrová; Ahmet Koc
Journal:  Antimicrob Agents Chemother       Date:  2019-08-23       Impact factor: 5.191

7.  Antifungal susceptibility profiles of bloodstream yeast isolates by Sensititre YeastOne over nine years at a large Italian teaching hospital.

Authors:  Brunella Posteraro; Teresa Spanu; Barbara Fiori; Flavio De Maio; Elena De Carolis; Alessia Giaquinto; Valentina Prete; Giulia De Angelis; Riccardo Torelli; Tiziana D'Inzeo; Antonietta Vella; Alessio De Luca; Mario Tumbarello; Walter Ricciardi; Maurizio Sanguinetti
Journal:  Antimicrob Agents Chemother       Date:  2015-04-20       Impact factor: 5.191

8.  Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.

Authors:  Thomas F Patterson; George R Thompson; David W Denning; Jay A Fishman; Susan Hadley; Raoul Herbrecht; Dimitrios P Kontoyiannis; Kieren A Marr; Vicki A Morrison; M Hong Nguyen; Brahm H Segal; William J Steinbach; David A Stevens; Thomas J Walsh; John R Wingard; Jo-Anne H Young; John E Bennett
Journal:  Clin Infect Dis       Date:  2016-06-29       Impact factor: 9.079

9.  Fluconazole and Voriconazole Resistance in Candida parapsilosis Is Conferred by Gain-of-Function Mutations in MRR1 Transcription Factor Gene.

Authors:  Joana Branco; Ana P Silva; Raquel M Silva; Ana Silva-Dias; Cidália Pina-Vaz; Geraldine Butler; Acácio G Rodrigues; Isabel M Miranda
Journal:  Antimicrob Agents Chemother       Date:  2015-07-27       Impact factor: 5.191

10.  New Triazole NT-a9 Has Potent Antifungal Efficacy against Cryptococcus neoformans In Vitro and In Vivo.

Authors:  Ren-Yi Lu; Ting-Jun-Hong Ni; Jing Wu; Lan Yan; Quan-Zhen Lv; Li-Ping Li; Da-Zhi Zhang; Yuan-Ying Jiang
Journal:  Antimicrob Agents Chemother       Date:  2020-01-27       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.